Nuclear Medicine: Page 25

GE announces first patient dosed with new PET radiopharmaceutical

By AuntMinnie.com staff writers

GE Healthcare announced that the first patient has been dosed in a phase III trial underway in France with a new dopamine transporter PET imaging radiopharmaceutical.

March 27, 2022

ITM promotes supply deal with Novartis for Pluvicto

By AuntMinnie.com staff writers

German radiopharmaceutical firm ITM Isotope Technologies Munich SE (ITM) highlighted its lutetium-177 supply deal with Novartis in the wake of the U.S. Food and Drug Administration's approval of the company's Pluvicto radioligand therapy.

March 24, 2022

Clarity launching trial for prostate cancer therapy

By AuntMinnie.com staff writers

Clarity Pharmaceuticals is launching an investigator-initiated trial that will focus on the use of its copper-64 (Cu-64)-labeled radiopharmaceutical, Cu-64 SAR-bisPSMA, in prostate cancer.

March 23, 2022

FDA approves Lu-177 PSMA-617 for prostate cancer treatment

By Will Morton

The U.S. Food and Drug Administration (FDA) has approved lutetium-177 (Lu-177) prostate-specific membrane antigen radioligand therapy for the treatment of patients with metastatic prostate cancer.

March 22, 2022

Eckert & Ziegler partners with Alpha-9 Theranostics

By AuntMinnie.com staff writers

Isotope technology firm Eckert & Ziegler has agreed to supply lutetium-177 to the Canadian biotechnology firm Alpha-9 Theranostics for use in clinical trials.

March 22, 2022

Navidea reports revenue declines in Q4, all of 2021

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals reported a decline in revenues for the fourth quarter of 2021 and the entire year.

March 22, 2022

FluoGuide gives details on brain cancer research in Denmark

By AuntMinnie.com staff writers

FluoGuide said a research grant connected to its work with Rigshospitalet in Copenhagen, Denmark, will help it set up a phase II trial for the company's FG001 radiopharmaceutical candidate in patients with less aggressive brain cancers.

March 17, 2022

Tc-99m SPECT/CT imaging detects COVID-19

By Will Morton

Iranian nuclear medicine physicians diagnosed COVID-19 in an asymptomatic patient undergoing technetium-99m (Tc-99m) SPECT/CT imaging for prostate cancer, according to a March 15 report in the Egyptian Journal of Radiology and Nuclear Medicine.

March 17, 2022

Dutch isotope reactor restarts

By AuntMinnie.com staff writers

The High Flux Reactor (HFR) in Petten, the Netherlands, has restarted after a forced shutdown due to a water leak in January, with isotopes deliveries to hospitals expected within two weeks.

March 16, 2022

AC Immune show first images from alpha-synuclein PET

By AuntMinnie.com staff writers

Swiss biopharmaceutical company AC Immune has revealed the first noninvasive live images of alpha-synuclein in humans' brains using its new PET tracer for neurogenerative diseases.

March 15, 2022

IBA and Tractebel partner on construction projects

By AuntMinnie.com staff writers

Proton therapy developer Ion Beam Applications (IBA) has inked a partnership agreement with engineering company Tractebel to support IBA's customers with their proton therapy design and construction projects.

March 14, 2022

SNMMI names radiopharma therapy centers of excellence

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named its first two designated radiopharmaceutical therapy centers of excellence: Stanford Health Care in Stanford, CA, and the Dana-Farber Brigham Cancer Center in Boston.

March 10, 2022

Previous Page

Page 25 of 440

Next Page